Interim Analysis of Platelet-Rich Plasma Treatment for Endocrine Therapy-Induced Alopecia and Permanent Chemotherapy-Induced Alopecia in Breast Cancer Patients: A Randomized Controlled Trial

    September 2024 in “ Journal of the American Academy of Dermatology ”
    Alexander Pan, Stephen W. Dusza, Sharif Hosein, Tara Maier, Kwami F. Ketosugbo, Céline Bravo, Saud Aleissa, Abdullah Aleisa, Christian Menzer, Mario E. Lacouture, Anthony Rossi
    New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
    The interim analysis of the randomized controlled trial on Platelet-Rich Plasma (PRP) treatment for Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in breast cancer patients indicates promising results. The study involved 100 participants, with 50 receiving PRP treatment and 50 in the control group. Preliminary findings show that PRP treatment significantly improved hair density and thickness in patients with EIA and pCIA compared to the control group. No severe adverse effects were reported, suggesting that PRP is a safe and effective option for managing hair loss in breast cancer patients undergoing endocrine therapy or chemotherapy. Further long-term studies are recommended to confirm these findings.
    Discuss this study in the Community →